Needham & Company Comments on ISIS Pharmaceuticals (ISIS) Following Data at ASH

Needham & Company analyst Chad Messer reiterated a Buy rating and $61 price target on ISIS Pharmaceuticals (NASDAQ: ISIS) after the company presented Phase II ISIS-FXIRx Data at ASH.

Messer commented, "ISIS released full Phase II ISIS-FXIRx data this morning concurrent with publication in the New England Journal of Medicine. The data will be the subject of a late-breaker session tomorrow at the American Society for Hematology (ASH) meeting. In patients undergoing total knee replacement (TKR), high dose ISIS-FXIRx demonstrated a significant reduction in venous thromboembolism (VTE), or blood clots in the veins, a common and potential serious side effect of the procedure. We believe these data are an important proof-of-concept for a potentially best-in-class anti-thrombotic agent

For an analyst ratings summary and ratings history on ISIS Pharmaceuticals click here. For more ratings news on ISIS Pharmaceuticals click here.

Shares of ISIS Pharmaceuticals closed at $52.76 yesterday.

You May Also Be Interested In

• OncoCyte Corp (OCX) PT Raised to $4.25 at Needham
• Equifax (EFX) PT Lowered to $263 at Citi
• Boston Scientific (BSX) PT Raised to $83 at Stifel